Loading...

Japan amends Pharmaceutical Affairs Act to attract Indian pharma

Image

29-Feb-16 The Japanese External Trade Organization (JETRO), which has set a foreign direct investment target of USD300 bn by 2020, is now wooing Indian pharmaceutical companies to maximize its conducive research-innovation ecosystem and advanced manufacturing infrastructure. To this end Japan has amended the Pharmaceutical Affairs Act, drastically improving the approval process for medicine and medical devices. [image: JETRO]

Read More

Half the world's population will be short-sighted by 2050

Image

18-Feb-16 If current trends continue, half the world’s population (4.8 bn people) will be short-sighted in just over three decades, with one-fifth of those expected to have a significantly increased risk of blindness. 96% of teenagers in Korea are short-sighted and in Singapore, China and Japan the rate is around 80-90%. [image: Nomad_Soul / Shutterstock.com]

Read More

Regulations hamstring smart healthcare in Korea

Image

01-Feb-16 At the 2012 Yeosu Expo, SK Telecom showcased its vision for remote healthcare. But "zero progress has been made on the smart health platform” said a manager at SK Telecom this year. “There is nothing we... can do about it because the law prohibiting remote diagnosis and treatment of patients remains unchanged." [image: Joongang Ilbo]

Read More

World’s first voice recognition system for diabetes management developed in Korea

Image

28-Jan-16 Seoul National University Bundang Hospital kept track of 99 diabetes patients aged 60+ for six months and found that those managed with its voice-recognition U-healthcare system showed a glycated hemoglobin level 8.5% lower than that of the control group. According to the hospital, this system can improve blood sugar management efficiency and help prevent diabetic complications. [image: Business Korea]

Read More

LG's new diabetes drug to begin global sales

Image

21-Jan-16 LG Life Sciences will start selling Korea's first diabetes treatment Zemiglo in the global market this year. The Korean drugmaker sealed licensing partnerships with Sanofi and Stendhal in 2013, and will begin selling the new treatment in India and five countries in Central America from March 2016. [image: LG / Business Korea]

Read More
Share